Allscripts Healthcare Solutions Investor Presentation — July 2020

Document content

Healthcare Solutions

Supplemental Investor Presentation © 2020 Allscripts Healthcare, LLC and/or its affiliates. 2

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . These forward -looking statements, including

targeted Adjusted EBITDA margins and other information regarding future performance included in this presentation, are based on the current beliefs and expectations of

Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. S uchstatements can be identified by the use of

words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “ could,” “can,” “may,” and similar terms. Actual results

could differ significantly from those set forth in the forward -looking statements and reported results should not be considered an indication of future performance. Certain

factors that could cause Allscripts actual results to differ materially from those described in the forward -looking statements i nclude, but are not limited to: the timing or

ultimate completion of the sale of our EPSi business, as the transaction is subject to certain closing conditions, including theexpiration or termination of the waiting period

under U.S. antitrust laws ; our use of the proceeds from the contemplated sale of our EPSi business; our ability to achieve the margin targets associated with our margin

improvement initiatives within the contemplated time periods, if at all; the magnitude, severity and duration of the COVID -19 pa ndemic, including the impacts of the

pandemic, along with the impacts of our responses and the responses by governments and other businesses to the pandemic, on o ur business, our employees, our clients and

our suppliers; the failure by Practice Fusion to comply with the terms of its settlement agreements with the U.S. Department of Justice (the “DOJ”); the costs and burdens of

compliance by Practice Fusion with the terms of its settlement agreements with the DOJ; additional investigations and proceed ings from governmental entities or third parties

other than the DOJ related to the same or similar conduct underlying the DOJ’s investigations into Practice Fusion’s business practices; our ability to recover from third

parties (including insurers) any amounts required to be paid in connection with Practice Fusion’s settlement agreements with the DOJ and related inquiries; the expected

financial results of businesses acquired by us; the successful integration of businesses recently acquired by us; the anticip ated and unanticipated expenses and liabilities related